Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Total Assets
Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) holds total assets worth CN¥452.07 Million CNY (≈ $66.15 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Total Assets Trend (1993–2025)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 600671 company net worth for the company's overall valuation and market capitalisation.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total assets of CN¥452.07 Million consist of 51.7% current assets and 48.3% non-current assets. Review 600671 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.2% |
| Accounts Receivable | CN¥143.84 Million | 32.5% |
| Inventory | CN¥39.18 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥5.01 Million | 1.1% |
| Goodwill | CN¥1.61 Million | 0.4% |
Asset Composition Trend (1993–2025)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hangzhou TianMuShan Pharmaceutical Enter (600671) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's current assets represent 51.7% of total assets in 2025, a decrease from 60.7% in 1993.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2025, up from 6.3% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 32.5% of total assets.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Total Assets
Key competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Roche Holding AG
SW:ROP
|
Switzerland | CHF100.70 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.84 | 0.79 | 0.80 |
| Quick Ratio | 0.71 | 0.60 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-46.34 Million | CN¥-52.97 Million | CN¥-50.52 Million |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 35.94 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | CN¥442.03 Million |
| Market Capitalization | $402.91 Million USD |
Valuation Analysis
Near Book Valuation: The market values Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2025)
The table below shows the annual total assets of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥442.03 Million ≈ $64.68 Million |
+0.13% |
| 2024-12-31 | CN¥441.46 Million ≈ $64.60 Million |
+27.48% |
| 2023-12-31 | CN¥346.29 Million ≈ $50.67 Million |
+15.49% |
| 2022-12-31 | CN¥299.84 Million ≈ $43.88 Million |
-25.53% |
| 2021-12-31 | CN¥402.65 Million ≈ $58.92 Million |
-9.01% |
| 2020-12-31 | CN¥442.51 Million ≈ $64.75 Million |
-16.02% |
| 2019-12-31 | CN¥526.93 Million ≈ $77.11 Million |
+9.64% |
| 2018-12-31 | CN¥480.62 Million ≈ $70.33 Million |
+6.70% |
| 2017-12-31 | CN¥450.44 Million ≈ $65.91 Million |
+47.11% |
| 2016-12-31 | CN¥306.19 Million ≈ $44.81 Million |
+9.21% |
| 2015-12-31 | CN¥280.38 Million ≈ $41.03 Million |
-1.84% |
| 2014-12-31 | CN¥285.64 Million ≈ $41.80 Million |
-12.18% |
| 2013-12-31 | CN¥325.27 Million ≈ $47.60 Million |
+9.92% |
| 2012-12-31 | CN¥295.92 Million ≈ $43.30 Million |
-17.30% |
| 2011-12-31 | CN¥357.84 Million ≈ $52.36 Million |
+11.90% |
| 2010-12-31 | CN¥319.79 Million ≈ $46.80 Million |
-2.58% |
| 2009-12-31 | CN¥328.27 Million ≈ $48.04 Million |
-11.06% |
| 2008-12-31 | CN¥369.08 Million ≈ $54.01 Million |
-10.87% |
| 2007-12-31 | CN¥414.09 Million ≈ $60.59 Million |
+17.48% |
| 2006-12-31 | CN¥352.47 Million ≈ $51.58 Million |
-5.43% |
| 2005-12-31 | CN¥372.71 Million ≈ $54.54 Million |
+4.15% |
| 2004-12-31 | CN¥357.85 Million ≈ $52.37 Million |
+3.27% |
| 2003-12-31 | CN¥346.52 Million ≈ $50.71 Million |
-7.23% |
| 2002-12-31 | CN¥373.53 Million ≈ $54.66 Million |
-8.62% |
| 2001-12-31 | CN¥408.75 Million ≈ $59.81 Million |
+0.71% |
| 2000-12-31 | CN¥405.88 Million ≈ $59.39 Million |
+19.45% |
| 1999-12-31 | CN¥339.78 Million ≈ $49.72 Million |
+5.19% |
| 1998-12-31 | CN¥323.01 Million ≈ $47.27 Million |
+9.24% |
| 1997-12-31 | CN¥295.69 Million ≈ $43.27 Million |
+14.02% |
| 1996-12-31 | CN¥259.33 Million ≈ $37.95 Million |
-1.40% |
| 1995-12-31 | CN¥263.02 Million ≈ $38.49 Million |
+36.90% |
| 1994-12-31 | CN¥192.12 Million ≈ $28.11 Million |
+69.27% |
| 1993-12-31 | CN¥113.50 Million ≈ $16.61 Million |
-- |
About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared sl… Read more